Novel agents for resistant Gram-positive infections - A review

Jacob Strahilevitz, Ethan Rubinstein*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations


Gram-positive infections have increased in recent years, particularly those that are of nosocomial origin, leading to a broad use of agents with activity against these pathogens. Concomitantly, antimicrobial resistance of these pathogens also became widespread. Among the most common Gram-positive resistant pathogens are: Streptococcus pneumoniae, resistant to penicillin and macrolides, methicillin-resistant Staphylococcus aureus (MRSA), glycopeptide- intermediately-resistant S. aureus (GISA), methicillin-resistant S. epidermidis, glycopeptide-resistant enterococci and vancomycin-resistant enterococci (VRE). The response of the pharmaceutical industry to this challenge was the development of new antibiotics active against these pathogens. Among these antibiotics, this review will focus on: linezolid, an oxazolidinone; GAR-936, a tetracycline derivative; daptomycin, a lipopeptide; and ortivancin (LY-333328), a glycopeptide related to vancomycin. Except for linezolid, which has been recently launched in many countries, all other agents referred to in this review are still at various developmental stages. It is hoped that in the near future most of these agents will be approved and thus the grim outlook of patients infected with resistant Gram-positive bacteria may improve.

Original languageAmerican English
Pages (from-to)S38-S46
JournalInternational Journal of Infectious Diseases
Issue numberSUPPL. 1
StatePublished - Mar 2002
Externally publishedYes


Dive into the research topics of 'Novel agents for resistant Gram-positive infections - A review'. Together they form a unique fingerprint.

Cite this